美股期权个股详情
ACXP241220P1000
- 0.05
- 0.000.00%
延时15分钟行情收盘价 11/26 16:00 (美东)
0.00最高价0.00最低价
0.05今开0.05昨收0张成交量31张未平仓合约数1.00行权价0.00成交额98.63%隐含波动率16.67%溢价2024/12/20到期日0.00内在价值100合约乘数23天距到期日0.05时间价值100合约规模美式期权类型-0.2552Delta1.1245Gamma22.80杠杆倍数-0.0019Theta-0.0002Rho-5.82有效杠杆0.0009Vega
Acurx Pharmaceuticals股票讨论
💰 BTC ETFs : $774.6M 📈
💰 ETH ETFs : -$30M 📉
⚡Elon Musk and Vivek Ramaswamy to launch "Dogecast" podcast for the #DOGE Department of Government Efficiency.
💰 BlackRock and Fidelity's spot #Bitcoin ETFs did a combined $4.17 BILLION in trading volume today
🔥 Biopharmaceutical company Acurx Pharmaceuticals is buying up to $1 million in #Bitcoin💰 as a treasury reserve asset
⚡️Bitwise registers for its #Solana💰 ETF in Delaware, per state d...
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Pharmaceuticals (NASDAQ: ACXP)announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were c...
Acurx Announces Additional Ibezapolstat Ph2B Results in Cdi as Well as Anthrax (B. Anthracis) Susceptibility to Acx-375 Analogues
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its mole...
oIn September 2024, the World Antimicrobial Resistance conference in Philadelphia;oIn September 2024,...
Uspto Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat Cdi While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the USPTO for ibezapolstat, its treatment for C. difficile Infection (CDI). The patent, issued on July 16, 2024, covers ibezapolstat's ability to treat CDI while reducing infection recurrence and improving gut microbiome health. This p...
暂无评论